The stock of Halyard Health Inc (NYSE:HYH) hit a new 52-week high and has $40.40 target or 8.00% above today’s $37.41 share price. The 5 months bullish chart indicates low risk for the $1.74 billion company. The 1-year high was reported on Nov, 29 by Barchart.com. If the $40.40 price target is reached, the company will be worth $139.20M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 335,976 shares traded hands. Halyard Health Inc (NYSE:HYH) has risen 16.88% since April 26, 2016 and is uptrending. It has outperformed by 11.62% the S&P500.
Analysts await Halyard Health Inc (NYSE:HYH) to report earnings on March, 6. They expect $0.45 earnings per share, down 21.05% or $0.12 from last year’s $0.57 per share. HYH’s profit will be $20.93M for 20.78 P/E if the $0.45 EPS becomes a reality. After $0.48 actual earnings per share reported by Halyard Health Inc for the previous quarter, Wall Street now forecasts -6.25% negative EPS growth.
Halyard Health Inc (NYSE:HYH) Ratings Coverage
Out of 6 analysts covering Halyard Health Inc (NYSE:HYH), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. Halyard Health Inc has been the topic of 12 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The company was maintained on Wednesday, August 10 by Deutsche Bank. Raymond James initiated Halyard Health Inc (NYSE:HYH) on Tuesday, July 21 with “Market Perform” rating. The firm earned “Sector Weight” rating on Friday, December 18 by KeyBanc Capital Markets. The firm has “Buy” rating given on Tuesday, June 14 by Stifel Nicolaus. The rating was initiated by Deutsche Bank with “Buy” on Friday, September 11. The stock of Halyard Health Inc (NYSE:HYH) has “Buy” rating given on Wednesday, January 27 by Stifel Nicolaus. Morgan Stanley downgraded the shares of HYH in a report on Monday, October 12 to “Underweight” rating. As per Friday, April 8, the company rating was initiated by Stephens. The stock of Halyard Health Inc (NYSE:HYH) has “Buy” rating given on Wednesday, December 2 by Stifel Nicolaus.
According to Zacks Investment Research, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia.”
More notable recent Halyard Health Inc (NYSE:HYH) news were published by: Prnewswire.com which released: “Halyard Health, Inc. to Present at Stifel 2016 Healthcare Conference” on November 10, 2016, also Wsj.com with their article: “Halyard Health Shares Climb as Profit Beats Expectations” published on May 04, 2016, Prnewswire.com published: “Halyard Health Announces Agreement to Acquire CORPAK MedSystems” on April 11, 2016. More interesting news about Halyard Health Inc (NYSE:HYH) were released by: Prnewswire.com and their article: “Halyard Health, Inc. to Present at Morgan Stanley Leveraged Finance Conference” published on November 03, 2016 as well as Prnewswire.com‘s news article titled: “Halyard Health, Inc. Year-End 2015 Results and 2016 Outlook” with publication date: February 29, 2016.
HYH Company Profile
Halyard Health, Inc., incorporated on February 25, 2014, seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Firm operates through two divisions: Surgical and Infection Prevention (S&IP) and Medical Devices. The Company’s S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections. The Medical Devices segment provides a portfolio of product offerings focused on pain management and respiratory and digestive health. The Company’s products and solutions are designed to address healthcare needs, such as preventing infection and reducing the use of narcotics while helping patients move from surgery to recovery. The Firm sells its products in approximately 100 countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.